BioSpace News Archive

Advance novel, late-stage Investigationalophthalmology drugs OCS-01 and OCS-02 and deliver the first topical drug for retinal edema.

Amgen Canada announced that AMGEVITA®, is now available in Canada for the treatment of 11 chronic inflammatory conditions.

Konica Minolta Precision Medicine, Inc. announced changes to its executive leadership team effective immediately.

the Epilepsy Foundation announced a collaboration with Eisai Inc. to develop a new platform — the Epilepsy Digital Experience Navigator — designed to empower people with epilepsy, their caregivers, and clinicians to use data to better understand and improve the epilepsy journey.

Micro Medical Solutions (MMS), an emerging leader in the treatment of CLTI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its MicroStent vascular stent

Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies for cancer, today announced the appointment of innovative oncology leader Johanna Kaufmann, Ph.D., as Executive Vice President, Oncology.

ExtriCARE USA, a national medical device company specializing in negative pressure wound therapy distribution, is excited to introduce hybrid technology to the wound care market.

Havn Life Sciences Inc., a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it now has a fully operational mycology lab and production facility in Jamaica.

In research to be shared during a plenary talk at the Society for Investigative Dermatology’s 2021 Virtual Meeting, data from investigators at the Tsai Lab at Moffitt Cancer Center, Sarin Lab at the Stanford University School of Medicine and NFlection Therapeutics demonstrate positive efficacy in preclinical models for the use of a topical gel — NFX-179 — to prevent cutaneous squamous cell carcinoma (cSCC).

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris Lowe, the company’s chief operating officer and chief financial officer, will participate in a fireside chat at the BofA Securities 2021 Healthcare Conference, a virtual event